3D Bioprinting Technology Developed By RBCC Partner n3D Biosciences Helps Researchers Create A Better In Vitro Breast Cancer Model
MIRAMAR BEACH, Fla.--(BUSINESS WIRE)--A Texas Medical Center research team has made a stunning breakthrough in breast cancer research using revolutionary 3D bioprinting technology being marketed and developed by Nano3D Biosciences (n3D), a joint venture partner of Rainbow Coral Corp. (OTCBB:RBCC).
Researchers were able to create a better in vitro model of breast cancer by magnetically levitating cells using n3D’s Bio-Assembler, part of the world’s first commercially available 3D bioprinting system designed for high throughput and high-content drug screening. By magnetically levitating cell cultures, the research team was able to replicate in vitro the cell heterogeneity of the tumor microenvironment.
Help employers find you! Check out all the jobs and post your resume.
Researchers were able to create a better in vitro model of breast cancer by magnetically levitating cells using n3D’s Bio-Assembler, part of the world’s first commercially available 3D bioprinting system designed for high throughput and high-content drug screening. By magnetically levitating cell cultures, the research team was able to replicate in vitro the cell heterogeneity of the tumor microenvironment.
Help employers find you! Check out all the jobs and post your resume.